Post-induction residual disease in translocation t(12;21)-positive childhood ALL
Jeanette Seyfarth MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorHans O. Madsen MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorCharlotte Nyvold MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorLars P. Ryder MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorNiels Clausen MD
Department of Pediatrics, University Hospital of Aarhus at Skejby, Denmark
Search for more papers by this authorGudmundur K. Jonmundsson MD
Department of Pediatrics, Landspitalinn Hospital, Reykjavik, Island
Search for more papers by this authorFinn Wesenberg MD
Department of Pediatrics, The University Hospital, Rikshospitalet, Oslo, Norway
Search for more papers by this authorCorresponding Author
Dr. Med Sci Kjeld Schmiegelow MD
Department of Pediatrics, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
The Juliane Marie Center 4064, The University Hospital, Rigshospitalet, Blegdamsvej, DK 2100 Copenhagen, Denmark.Search for more papers by this authorJeanette Seyfarth MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorHans O. Madsen MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorCharlotte Nyvold MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorLars P. Ryder MSc
Department of Clinical Immunology, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
Search for more papers by this authorNiels Clausen MD
Department of Pediatrics, University Hospital of Aarhus at Skejby, Denmark
Search for more papers by this authorGudmundur K. Jonmundsson MD
Department of Pediatrics, Landspitalinn Hospital, Reykjavik, Island
Search for more papers by this authorFinn Wesenberg MD
Department of Pediatrics, The University Hospital, Rikshospitalet, Oslo, Norway
Search for more papers by this authorCorresponding Author
Dr. Med Sci Kjeld Schmiegelow MD
Department of Pediatrics, The National University Hospital, Rigshospitalet, Copenhagen, Denmark
The Juliane Marie Center 4064, The University Hospital, Rigshospitalet, Blegdamsvej, DK 2100 Copenhagen, Denmark.Search for more papers by this authorAbstract
Background
t(12;21)(p1 3;q22), the most frequent chromosomal translocation found in childhood acute lymphoblastic leukemia (ALL), occurs in ∼ 25% of B-lineage ALL cases and has been claimed to carry a good prognosis.
Procedure
As part of the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL-MRD 95 study, which includes children from Iceland, Norway, and Denmark diagnose d with ALL, patients were screened for the presence of t(12; 21) by reverse transcriptase-polymerase chain reaction (RT-PCR) at diagnosis, and their residual disease was quantified after 4 weeks of induction therapy (prednisolone, vincristine, doxorubicin, i.t. methotrexate) by a competitive, clone-specific, semi-nested PCR analysis.
Results
Among 96 children diagnosed with ALL, and quantified for post induction residual disease, 32 were t(12;21)-positive. The median residual disease was similar for B-precursor ALL patients with and without t(12;21) (0.009 vs. 0.03%, P = 0.12).
Conclusions
Al though patients with t(12;21)-positive ALL have been claimed to have a good outcome, these data indicate that this does not reflect a high sensitivity to prednisolone, vincristine, and doxo rubicin given during induction therapy. Med Pediatr Oncol 2003;40:82–87. © 2003 Wiley-Liss, Inc.
REFERENCES
- 1 Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000; 14: 2267–2275.
- 2 Rubnitz JE, Look AT. Molecular genetics of childhood leukemias. J Pediatr Hematol Oncol 1998; 20: 1–11.
- 3 Aguiar RC, Sohal J, van Rhee F, et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol 1996; 95: 673–677.
- 4 Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel–AML1 gene fusion. Blood 1995; 85: 3662–3670.
- 5 Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917–4921.
- 6 Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985–1989.
- 7 McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252–4258.
- 8 Rubnitz JE, Shuster JJ, Land VJ, et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group Study. Blood 1997; 89: 1143–1146.
- 9 Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997; 15: 1150–1157.
- 10 Zuna J, Hrusak O, Kalinova M, et al. TEL/AML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia 1999; 13: 22–24.
- 11 Seeger K, Buchwald D, Peter A, et al. TEL–AML1 fusion in relapsed childhood acute lymphoblastic leukemia. Blood 1999; 94: 374–376.
- 12 Ayigad S, Kuperstein G, Zilberstein J, et al. TEL–AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 481–483.
- 13 Rubnitz JE, Behm FG, Wichlan D, et al. Low frequency of TEL–AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999; 13: 19–21.
- 14 Seeger K, Buchwald D, Taube T, et al. TEL–AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Berlin-Frankfurt-Munster Study Group. Leukemia 1999; 13: 1469–1470.
- 15 Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1989; 7: 1807–1815.
- 16 Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group phase III trial. J Clin Oncol 1993; 11: 527–537.
- 17 Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273–279.
- 18 Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196–200.
- 19 Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550–554.
- 20 Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer—Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591–598.
- 21 Schmiegelow K, Nyvold C, Seyfarth J, et al. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in-vitro prednisolone resistance. Leukemia 2001; 15: 1066–1071.
- 22 Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253–1258.
- 23 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
- 24 Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263–4269.
- 25 Kimura A, Sasazuki T. Eleventh international histocompatibility workshop reference protocol for the HLA DNA-typing technique. In: K Tsuji, M Aizawa, T Sasazuki, editors. HLA 1991. Oxford: Oxford University Press; 1992. 397–419.
- 26 Nyvold C, Madsen HO, Ryder LP, et al. Competitive PCR for quantification of minimal residual disease in acute lymphoblastic leukaemia. J Immunol Methods 2000; 233: 107–118.
- 27 Siegel S, Castellan NJ. Nonparametric statistics for the behavioral sciences. Singapore: McGrawHill; 1988.
- 28 Kaplan EJ, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
- 29 Wasserman R, Galili N, Ito Y, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879–1888.
- 30 van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.
- 31 Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140–146.
- 32 Nakao M, Yokota S, Horiike S, et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 1463–1470.
- 33 Cayuela JM, Baruchel A, Orange C, et al. TEL–AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996; 88: 302–308.
- 34
Pallisgaard N,
Clausen N,
Schroder H, et al.
Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL–AML1 fusion transcript.
Genes Chromosomes Cancer
1999;
26:
355–365.
10.1002/(SICI)1098-2264(199912)26:4<355::AID-GCC10>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 35 Andersen MT, Nordentoft I, Hjalgrim LL, et al. Characterization of t(12;21) breakpoint junctions in acute lymphoblastic leukemia. Leukemia 2001; 15: 858–859.
- 36 Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571–577.
- 37 Fasching K, Konig M, Hettinger K, et al. MRD levels during the first months of treatment indicate relapses in children with t(12;21)-positive ALL [Letter]. Leukemia 2000; 14: 1707–1708.
- 38 Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000; 96: 1094–1099.
